Alpha-Tectorin, Interleukin-10 and Thiol-Disulfide Homeostasis in Children With Congenital Hearing Loss
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Harran University
- Trial code
- NCT07860580
- Record updated
- 6 October 2026
- Original description
Congenital hearing loss is one of the most common sensory disorders of childhood, and the structural, immunologic and oxidative mechanisms involved in its development are incompletely understood. This case-control study aims to evaluate serum alpha-tectorin and interleukin-10 (IL-10) levels and thiol-disulfide homeostasis in children with congenital sensorineural hearing loss (cochlear implant users and hearing aid users) compared with healthy children with normal hearing. The findings are expected to contribute to a better understanding of the mechanisms underlying congenital hearing loss and to the identification of potential diagnostic and prognostic biomarkers.Read full original descriptionShow less
Evaluation of Alpha-Tectorin, Interleukin-10, and Thiol-Disulfide Homeostasis in Individuals With Congenital Hearing Loss
Congenital hearing loss is one of the most common sensory disorders of childhood, and the structural, immunologic and oxidative mechanisms involved in its development are incompletely understood. This case-control study aims to evaluate serum alpha-tectorin and interleukin-10 (IL-10) levels and thiol-disulfide homeostasis in children with congenital sensorineural hearing loss (cochlear implant users and hearing aid users) compared with healthy children with normal hearing. The findings are expected to contribute to a better understanding of the mechanisms underlying congenital hearing loss and to the identification of potential diagnostic and prognostic biomarkers.
Inclusion: Congenital Hearing Loss Groups (Cochlear Implant Group and Hearing Aid Group); Age under 18 years; Congenital sensorineural hearing loss diagnosed at the Otorhinolaryngology outpatient clinic and confirmed by audiological testing (auditory brainstem response, otoacoustic emissions and/or pure-tone audiometry); Active use of a cochlear implant (Cochlear Implant Group) or active use of a hearing aid without cochlear implantation (Hearing Aid Group); No condition preventing collection of a peripheral blood sample; Written informed consent from the parent or legal guardian; Healthy Control Group; Age under 18 years; No diagnosis of hearing loss and normal audiological evaluation; No condition preventing collection of a peripheral blood sample; Written informed consent from the parent or legal guardian.
Exclusion: Immunodeficiency or use of immunosuppressive therapy; Use of systemic corticosteroids, biologic agents or immunomodulatory therapy within the last 4 weeks; Acute infection, chronic inflammatory disease, autoimmune disease or other systemic disease; History of malignancy or active malignant disease; Syndromic hearing loss.